Does sertraline come in 150 mg tablet? (3 differences)
By
Ivan Kahwa
Author bio
Mr Ivan Kahwa is a chemist and phytopharmaceutical scientist with expertise in chemistry, pharmacology, phytochemistry, and Nanobiotechnology. He writes and reviews content on these topics.
Mr Ivan Kahwa’s Highlights:
Guest Researcher at the University of Leipzig, Senior Research Fellow/Scientist, and Lecturer at the Department of Pharmacy, Faculty of Medicine, Mbarara University of Science and Technology.
Professional Experience:
Mr Ivan joined PHARMBIOTRAC as a research fellow/scientist during his master of science tenure. He contributed to the development of most of the phytopharmaceutical products in the project. Furthermore, he participated in carrying out the pharmacological activities of the developed products in laboratory animals such as mice and rats in order to develop proper doses hence leading to pre-clinical studies.
With the above relevant research experience, Ivan started to work with the University of Leipzig on collaborative projects with Mbarara University to develop the chemistry of Ugandan Medicinal plants and their pharmacological activities. This was coupled with several consultative positions by different German NGOs. Mr. Kahwa is also a supporting in the teaching and learning at the Departments of Pharmacy and Pharmaceutical Sciences, Faculty of Medicine, Mbarara University of Science and Technology.
With the increase in antimicrobial resistance globally, Ivan retooled his thinking towards developing new naturally derived antibiotic regimens from Ugandan propolis with the assistance of nanotechnology to improve their delivery to microbial cells. Kahwa has also published over 28 articles in peer-reviewed journals and he is currently reviewing for many journals.
Education:
2023-2027: PhD in Pharmaceutical Sciences (ongoing) with a focus on Pharmaceutical Microbiology and Nanobiology at Mbarara University of Science and Technology.
2022: 2Msc. in Pharmacognosy and Natural Medicine Science at Mbarara University of Science and Technology.
2018: Bachelor of Science (Chemistry) at Mbarara University of Science and Technology.
Publications:
▪ Iqbal, S., Jabeen, F., Kahwa, I., & Omara, T. 2023. Suberosin Alleviates Thiazolidinedione-Induced Cardiomyopathy in Diabetic Rats by Inhibiting Ferroptosis via Modulation of ACSL4-LPCAT3 and PI3K-AKT Signaling Pathways. Cardiovascular Toxicology. https://doi.org/10.1007/s12012-023-09804-7
▪ Gupta, A. K., Yadav, R., Sharma, S., Sawale, J., & Kahwa, I. 2023. Anti-ageing Activity and Antioxidant Activity of Methanol Extracts of Leaves and Flowers of Salvia officinalis and Rosmarinus officinalis. Journal of Young Pharmacists, 15(3), 448–455. https://doi.org/10.5530/jyp.2023.15.60
▪ Tolo, C.U., Kahwa, I., Nuwagira, U., Weisheit, A. and Ikiriza, H., 2023. Medicinal plants used in treatment of various diseases in the Rwenzori Region, Western Uganda. Ethnobotany Research and Applications, 25, pp.1-16.
https://ethnobotanyjournal.org/index.php/era/article/view/4683
▪ Kahwa, I., Ajayi, C.O., Yadav, R., Chauhan, N.S., Shah, K., Abdelgadir, A.A., Shegena, E.A., Daniel, S., Omara, T., Asiimwe, J.B. and Ikiriza, H., 2023. Pharmacognostic and phytochemical studies as an invaluable approach for correct identification of medicinal plants: The case of Artemisia vulgaris L. substituted for Artemisia annua L. in Western Uganda. TMR Integr Med, 7, p.e23004.
https://doi.org/10.53388/TMRIM202307004
▪ Nalimu, F., Oloro, J., Kahwa, I. and Ogwang, P.E., 2021. Review on the phytochemistry and toxicological profiles of Aloe vera and Aloe ferox. Future Journal of Pharmaceutical Sciences, 7, pp.1-21.
https://doi.org/10.1186/s43094-021-00296-2
▪ Elamin, O.H.S., Ali, M.A., Elgezuli, I.A.A., Bashir, M.A. and Kahwa, I., 2021. Diagnosis of pre-and post-treatment of echinococcus granulosus with counter current immune electrophoresis and bacterial co-agglutination. Journal of Microbiology and Infectious Diseases, 11(02), pp.88-94.
https://doi.org/10.5799/jmid.951600
Published book Chapter
▪ Kahwa, I., Ayesiga, I., Nakalema, S., Alinaiswe, R., Mbabazi, R. and Iqbal, S., 2023. Natural products in the management of onchocerciasis. In Natural Products in Vector-Borne Disease Management (pp. 63-80). Academic Press. Book Chapter.
https://doi.org/10.1016/B978-0-323-91942-5.00012-4
Submitted manuscripts Under Review:
▪ Comparison of the Wound Healing Activity of the Leaf and Leaf Ash Extracts of Vernonia amygdalina in Rats. Journal name: Clinical Phytoscience
▪ Ethnobotanical Survey of Medicinal plants used in the management of cancer in Uganda. Journal name: Journal of Herbal Medicine
▪ Ethnobotanical survey and phytochemical screening of medicinal plants used in treatment of epilepsy by PROMETRA-Uganda Traditional Health Practitioners in Mpigi District, Uganda. Journal name: Journal of Ethnopharmacology
Submitted book chapters under review
1.Book title: Algae as a Natural Solution for Water-Food-Energy Nexus, Section 4: Microalgae and cyanobacteria for food applications, Chapter 4.6: Safety, toxicological and allergenic aspects of using algae for food. Authors: Christine Kyarimpa, Tom Omute, Caroline K. Nakiguli, Alice V. Khanakwa4, Christopher Angiro, Ivan Kahwa, Fortunate Ahumuza, Timothy Omara*. Publisher: Springer Nature Singapore Pte Ltd. 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore.
2.Book title: Nutraceuticals Inspiring the Contemporary Therapy for Lifestyle Diseases. Chapter: Nutraceutical applications of Seaweeds and their Phytocompounds in Nutrition and Treatment of Diseases. Authors: Ivan Kahwa, Timothy Omara , Innocent Ayesiga , Gael Noel Neh Neba Ambe , Zehbanaz Javidbhai Panwala , Rachel Mbabazi , Shabnoor Iqbal , Christine Kyarimpa , Christine Betty Nagawa , Kamal Shah ,Nagendra Singh Chauhan* Publisher: CRC Press
You can view my works on the following professional sites:
Research Gate: https://www.researchgate.net/profile/Ivan-Kahwa
Google Scholar: https://scholar.google.com/citations?user=tOwrvqoAAAAJ&hl=en
ORCID: https://orcid.org/0000-0002-6440-3437
Linkedin: https://de.linkedin.com/in/ivan-kahwa-865450159
This article will answer the question: ‘Is Sertraline available in 150 mg tablet form?’ Furthermore, we will delve into the various available dosage forms, highlighting their distinctions.
Does Sertraline come in 150 mg tablet?
Sertraline is not available in 150 mg tablet form. Instead, 150 mg of sertraline is available in capsule form.
The tablet form of sertraline comes in strengths of 25 mg, 50 mg, and 100 mg, while the 150 and 200 mg strengths are found in capsules. (1)
What is the difference between Sertraline tablets and capsules?
Sertraline is a widely prescribed medication used to manage various mental health conditions. It is available in two primary forms: tablets and capsules. While both forms serve the same therapeutic purpose, they differ in dosage forms. (1)
Tablets are solid forms of the medication, containing drugs and excipients. Capsules encase the medication in a shell, which dissolves in the digestive tract to release the drug.
Sertraline tablets come in several strengths, such as 25 mg, 50 mg, and 100 mg. Capsules are typically available in higher strengths, like 150 and 200 mg. (1,2)
Sertraline tablets are often designed to be split or crushed if necessary. Sertraline capsules should not be crushed or split, as it may compromise their effectiveness.
Both forms are administered orally and act in a similar manner within the body. The choice between tablets and capsules is influenced by dosage requirements.
Is 150 mg Sertraline too high?
The initial dosage of sertraline is a crucial decision in the treatment process, and it’s common for individuals to wonder if 150 mg is too high, to begin with.
Starting with a 150 mg dose of sertraline is generally considered high and is not the typical approach. Healthcare providers often initiate treatment with lower doses to gauge an individual’s response and minimise the risk of potential side effects.
Usually, Sertraline is titrated and the treatment is started with lower strengths, such as 25 mg or 50 mg. These lower doses serve as a starting point, allowing healthcare providers to assess how the medication affects the patient and whether adjustments are needed.
Over time, if necessary, the dose can be gradually increased, with a maximum recommended dose of 200 mg per day. This incremental approach helps tailor the treatment to the individual’s needs and ensures safety.
Healthcare providers often prescribe 25 mg or 50 mg tablets for starting doses. If your condition requires a higher dosage, such as 150 mg, they may transition you to sertraline capsules. Your healthcare provider carefully manages this shift to ensure a seamless transition. (3)
Some conditions that commonly need a 150 mg maintained dose include Major Depressive Disorder (MDD), Panic Disorder (PD), and Obsessive-Compulsive Disorder (OCD). These conditions may require higher doses to manage symptoms effectively. (2)
It’s important to understand that sertraline, like many antidepressants, may take time for your body to adjust to and for therapeutic effects to become noticeable. Patience is critical during this process.
What are the side effects of the 150 mg Sertraline dose?
Here’s a list of some crucial side effects to look out for if you suspect 150 mg sertraline dose is high: (1,2)
- Severe Nausea
- Persistent Sweating
- Extreme Irritability
- Agitation
- Dizziness
- Sensory Disturbances (like paresthesia)
- Confusion
- Headache
- Stomach upset
These side effects can be indicators that your dosage may be too high, and it’s essential to promptly consult your healthcare provider if you experience any of these symptoms. They can assess your condition and make any necessary adjustments to your medication regimen.
Is it possible to switch from Sertraline capsules to tablets?
Indeed, it is possible to switch from sertraline capsules to tablets under the guidance of your healthcare provider. Your doctor will prescribe the tablets as part of a tapering plan or if you’re transitioning from 150 mg capsules to a lower dose.
It is always advised to not abruptly stop taking Sertraline. Gradually reducing the dose is important to avoid withdrawal effects. Since the lowest dose available in capsules is 150 mg, a gradual reduction of sertraline may necessitate using 100 mg, 50 mg, or 25 mg tablets.
Your healthcare provider will carefully tailor this transition to ensure your treatment remains effective and well-managed. Always consult your healthcare provider before making any changes to your medication regimen.
Conclusion
In conclusion, Sertraline is not available in 150 mg tablet form. Instead, 150 mg of sertraline is found in capsule form. Sertraline tablets are offered in strengths of 25 mg, 50 mg, and 100 mg, while the 150 and 200 mg strengths are available in capsules. Always consult a healthcare professional for accurate and safe medication management tailored to your needs.
Was this helpful?
References
Find a supportive therapist who can help with Depression.
Discover the convenience of BetterHelp, an online therapy platform connecting you with licensed and accredited therapists specialized in addressing issues such as depression, anxiety, relationships, and more. Complete the assessment and find your ideal therapist within just 48 hours.
AskYourPharm is user-supported. We may earn a commission if you sign up for BetterHelp’s services after clicking through from this site
